The Cough drug market size in Kenya stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period
Cough is a common symptom of upper and lower respiratory tract infections. It is a reflex response to a mechanical, chemical or inflammatory irritant in the tracheobronchial tree. Cough can be acute or chronic based on the length of cough. Cough lasting for more than eight weeks is called chronic chough. Some of the respiratory diseases presenting cough as a cardinal symptom include tuberculosis, pneumonia, asthma and COPD which are highly prevalent in Kenya. Antitussives are widely used to relieve the symptoms of cough.
The market is majorly driven by high prevalence of respiratory infections like Tuberculosis in Kenya. Tuberculosis (TB) is a serious public health issue in Kenya. About 120,000 people develop TB (48,000 of them being HIV-positive) and 18,600 people die from it every year.
The sequential lifestyle changes that are occurring in the Kenya because of rapid urbanisation, increased exposure to environmental and occupational pollution and smoking are believed to be accelerating the development of asthma.
There is uncontrolled or unregulated exposure to many irritant pollutants such as dust, smoke and pesticides. The risk and intensity of exposure to these harmful irritants amongst different vulnerable population groups continues to increase due to the lack of clear regulatory policies particularly in informal occupational settings.
The market is also driven by the presence of strong and robust pipeline drugs in the market to relieve cough symptoms.